Author

Yasong Lu

Institution: Bicycle Therapeutics (United Kingdom)

Observed institutions: Bicycle Therapeutics (United Kingdom), Daiichi Sankyo (United States)

ORCID: 0000-0002-9387-7340

Observed ORCID: 0000-0002-9387-7340

OpenAlex ID: A5031887017

A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas

2023 · Mrinal M. Gounder, Todd M. Bauer, et al. · Journal of Clinical Oncology · 111

TROPION-PanTumor01: Dose analysis of the TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062) for the treatment (Tx) of advanced or metastatic non-small cell lung cancer (NSCLC).

2021 · Funda Meric-Bernstam, Alexander I. Spira, et al. · Journal of Clinical Oncology · 32

Application of the model‐informed drug development paradigm to datopotamab deruxtecan dose selection for late‐stage development

2023 · Yasong Lu, Shuang Liang, et al. · CPT Pharmacometrics & Systems Pharmacology · 16

Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors

2022 · Yasong Lu, Shinji Shimizu, et al. · The Journal of Clinical Pharmacology · 10

Breaking from the paradigm of antibody-drug conjugates: Evaluation of clinical pharmacokinetics and safety of bicycle toxin conjugates (BTCs).

2024 · Justin Bader, Meredith McKean, et al. · Journal of Clinical Oncology · 4

Identifying optimized dosage for zelenectide pevedotin in locally advanced/metastatic urothelial carcinoma (la/mUC) using quantitative analyses.

2026 · Yasong Lu, Justin Bader, et al. · Journal of Clinical Oncology

Application of Model Informed Drug Development (MIDD) to BT8009, a Bicycle Toxin Conjugate (BTC®), in Patients with Advanced Urothelial Cancer

2024 · Yasong Lu, Zixu Wang, et al.

Works count: 7

Citation count: 173

H-index: 4

I10-index: 4